• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Intraarticular Injection of Infliximab not Effective in Patients with Inflammatory Arthritis

Intraarticular Injection of Infliximab not Effective in Patients with Inflammatory Arthritis

July 15, 2009 By Arthritis Center

Intraarticular Injection
Intraarticular Injection

Despite systemic administered therapies, some patients with inflammatory arthritis continue to have chronic or recurrent joint inflammation in one or a few joints.  Intraarticular glucocorticoids are often used with success in these patients; however, injections often have to be repeated periodically and there are concerns for the long-term consequences of injected glucocorticoids.  Intraarticular injection of anti-TNF therapy is an attractive, but largely unstudied, option, as these agents have been shown to be very effective in reducing the disease activity of a number of chronic inflammatory conditions.  In this proof-of-concept study, van der Bijl et al (Arthritis Care & Research 2009; 61(7): 974) explore the efficacy and safety of intraarticular infliximab compared to intraarticular methylprednisolone.

Methods

Adult patients without infection, gout, or osteoarthritis with a chronically inflamed knee despite one or more steroid injections within the past year were randomized to receive either an intraarticular injection of infliximab (100 mg) or methylprednisolone (80 mg).  A second injection (randomly assigned) was given for recurrent symptoms within 3 months.  Inefficacy was defined as the need for any retreatment (injection or surgical) at the 3 and 6 month follow-up visits.  In all patients, aspiration was performed prior to injection by an investigator blinded to treatment allocation.  The remaining investigators, study staff, and the patients were blinded to treatment allocation.

Results

A total of 23 patients were treated, with a total of 28 knees injected (15 knees were randomized to receive their first injection with infliximab and 13 with methyprednisolone).  Inefficacy was noted in all 15 knees initially randomized to infliximab.  Of these, 1 was reinjected with infliximab (not effective) and 8 were injected with methylprednisolone (1 of 8 effective).  Of the 13 knees initially randomized to methylprednisolone, 7 were ineffective.  Infliximab was injected into 4 of these, with none determined to be effective.  In total, none of the 20 injections of infliximab were deemed effective, compared to 8 of the 21 injections of methylprednisolone (38%; p=0.004 compared to infliximab).  Time to failure after injection was more rapid for the infliximab treated knees considering only the first injections and all injections.  Clinical characteristics did not differ according to treatment allocation.  There were no treatment related adverse events in either group.

Conclusions

For patients with chronic knee inflammation, intraarticular infliximab was not an effective at reducing signs or symptoms of inflammation, or delaying the need for additional treatments.  Intraarticular methylprednisolone was effective in only a fraction of patients.

Editorial Comment

Using injected TNF inhibitors as adjunctive therapy for single difficult to treat joints is a compelling hypothesis; however, the findings from this investigation are quite suggestive of the futility of this strategy.  The reasons for the lack of improvement are not clear.  It is possible that infliximab injected into the synovial fluid is not absorbed into the deep synovium, where many of the processes driving synovitis are located.  Another possibility could be that the properties of the infliximab antibody itself facilitates, rather than abrogates, inflammation within the joint (although it is not indicated that patients had worsening of their joint inflammation after injection).  Regardless of mechanism, the lack of any improvement with intraarticular infliximab in this trial should discourage practitioners from using this off-label treatment.  While also not effective in many of the patients, intraarticular glucocorticoids remain an inexpensive and generally safe option.  However, this study demonstrates that other treatment options are needed for patients with difficult to treat “stubborn” joints with persistent inflammation.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy